BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing

Bulletin Express

08/14

BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.

The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.

Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1193188148"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1193188148\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1193188148?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193188148","market":"us","top_or_hot":-1,"title":"BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing","media":"Bulletin Express","content":"<p>BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.</p>\n<p>The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.</p>\n<p>Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines Schedules 26 Aug 2026 Audit Committee Meeting to Approve 1H26 Results Aligned with Earlier U.S. Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-14 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.</p>\n<p>The forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.</p>\n<p>Corporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1193188148","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193188148","pubTimestamp":1786699592,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"BeOne Medicines 计划于 2026 年 8 月 26 日召开审计委员会会议，批准 26 年上半年业绩，与之前的美国文件一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"BeOne Medicines Ltd. (BeOne Medicines) has announced that its board audit committee will convene on 26 August 2026 (Hong Kong time) to consider and approve the interim results for the six months ended 30 June 2026 and authorise their release under Hong Kong Listing Rules.\nThe forthcoming disclosure will mirror the interim results previously released on 5 August 2026 in the company’s Form 10-Q filed with the U.S. Securities and Exchange Commission. The Hong Kong version will incorporate additional information mandated by local listing regulations, including a reconciliation from U.S. GAAP to IFRS.\nCorporate governance remains unchanged. The board comprises Chairman and Executive Director Mr. John V. Oyler; Non-executive Directors Dr. Felix J. Baker and Dr. Xiaodong Wang; and Independent Non-executive Directors Dr. Olivier Brandicourt, Dr. Margaret Han Dugan, Mr. Anthony C. Hooper, Ms. Elizabeth F. Mooney, Dr. Alessandro Riva, Dr. Charles L. Sawyers and Ms. Shalini Sharp.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}